Viromed Medical AG (Q11) - Net Assets
Based on the latest financial reports, Viromed Medical AG (Q11) has net assets worth €269.20 Million EUR (≈ $314.72 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€339.03 Million ≈ $396.36 Million USD) and total liabilities (€69.84 Million ≈ $81.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Viromed Medical AG to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €269.20 Million |
| % of Total Assets | 79.4% |
| Annual Growth Rate | 71.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 89.31 |
Viromed Medical AG - Net Assets Trend (2021–2024)
This chart illustrates how Viromed Medical AG's net assets have evolved over time, based on quarterly financial data. Also explore how large is Viromed Medical AG's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Viromed Medical AG (2021–2024)
The table below shows the annual net assets of Viromed Medical AG from 2021 to 2024. For live valuation and market cap data, see Q11 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €201.16 Million ≈ $235.17 Million |
+212.95% |
| 2023-12-31 | €64.28 Million ≈ $75.15 Million |
+1.66% |
| 2022-12-31 | €63.23 Million ≈ $73.92 Million |
+58.19% |
| 2021-12-31 | €39.97 Million ≈ $46.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Viromed Medical AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4618861400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €299.14 Million | 148.71% |
| Total Equity | €201.16 Million | 100.00% |
Viromed Medical AG Competitors by Market Cap
The table below lists competitors of Viromed Medical AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Continental Holdings Corp
TW:3703
|
$538.17 Million |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
$538.28 Million |
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
$538.40 Million |
|
Mahindra Holidays & Resorts India Limited
NSE:MHRIL
|
$538.74 Million |
|
Nanjing Well Pharmaceutical Co Ltd
SHG:603351
|
$537.89 Million |
|
IS Dongseo
KO:010780
|
$537.84 Million |
|
Neosem Inc
KQ:253590
|
$537.71 Million |
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
$537.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viromed Medical AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 64,278,637 to 201,157,576, a change of 136,878,939 (212.9%).
- Net loss of 23,456,138 reduced equity.
- New share issuances of 127,679,865 increased equity.
- Other factors increased equity by 32,655,212.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.46 Million | -11.66% |
| Share Issuances | €127.68 Million | +63.47% |
| Other Changes | €32.66 Million | +16.23% |
| Total Change | €- | 212.95% |
Book Value vs Market Value Analysis
This analysis compares Viromed Medical AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 30.80x to 13.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.23 | €6.95 | x |
| 2022-12-31 | €0.24 | €6.95 | x |
| 2023-12-31 | €0.24 | €6.95 | x |
| 2024-12-31 | €0.51 | €6.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viromed Medical AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-11.66%) is above the historical average (-27.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -61.77% | 0.00% | 0.00x | 1.07x | €-28.69 Million |
| 2022 | -34.63% | 0.00% | 0.00x | 1.03x | €-28.22 Million |
| 2023 | -1.30% | 0.00% | 0.00x | 1.67x | €-7.26 Million |
| 2024 | -11.66% | 0.00% | 0.00x | 1.27x | €-43.57 Million |
Industry Comparison
This section compares Viromed Medical AG's net assets metrics with peer companies in the Gold industry.
Industry Context
- Industry: Gold
- Average net assets among peers: $12,388,487
- Average return on equity (ROE) among peers: -46.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viromed Medical AG (Q11) | €269.20 Million | -61.77% | 0.26x | $537.97 Million |
| Pearl Gold AG (02P) | $0.00 | 0.00% | 0.00x | $12.86 Million |
| Asante Gold Corporation (1A9) | $3.53 Million | -19.08% | 0.79x | $640.51 Million |
| American Pacific Mining Corp (1QC1) | $41.94 Million | -24.06% | 0.02x | $19.08 Million |
| SITKA GOLD CORP (1RF) | $43.88 Million | -7.79% | 0.14x | $236.82 Million |
| GREENHAWK RESOURCES INC. (2V70) | $5.66 Million | -275.28% | 0.01x | $50.39K |
| THETA GOLD MNS LTD (3LM) | $8.69 Million | -50.24% | 1.23x | $149.39 Million |
| McLaren Resources Inc (3ML) | $398.20K | -80.71% | 0.21x | $2.42 Million |
| Tarachi Gold Corp (4RZ) | $3.36 Million | 12.54% | 0.01x | $2.42 Million |
| KATORO GOLD PLC LS-01 (622) | $-325.46K | 0.00% | 0.00x | $1.74 Million |
| Blue Lagoon Resources Inc (7BL) | $16.76 Million | -23.25% | 0.47x | $76.21 Million |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.